PARP Inhibitors Bring Encouraging Results
SHARE

Medically Reviewed
SurvivorNet Fact Checking and Medical Review Standards:   The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts. All SurvivorNet articles adhere to the following standards:
  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles
6) Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated February 14th, 2022

PARP Inhibitors Bring Encouraging Results

Medically Reviewed: Dr. Monica Vetter Written by Dr. Ursula Matulonis
Dana-Farber Cancer Institute
×

PARP Inhibitors Bring Encouraging Results to Ovarian Cancer Patients

  • PARP inhibitors are a kind of therapy that inhibit targeted proteins (PARP proteins) in cancer cells, which causes cell death amongst cancerous cells.
  • The drugs are an option for women as maintenance therapy after first chemotherapy or platinum sensitive recurrence, or as treatment for recurrence.
  • There are different types of PARP inhibitors available for women with ovarian cancer, including Lynparza (olaparib), Zejula (niraparib), and Rubraca (rucaparib).
  • The different PARP inhibitors do have some varying side effects, which oncologists need to evaluate carefully.
The last few years have been encouraging for the physicians, patients, and pharmaceutical companies battling ovarian cancer. In large part, this optimism stems from the development of poly (ADP-ribose) polymerase (PARP) inhibitors, which in recent years were approved as a targeted therapy treatment, and which have subsequently led to longer progression-free survival rates.

How PARP Inhibitors Work

One of the key things to know about PARP inhibitors is that your genetic makeup and specific features of your cancer will have a significant impact on how effective these drugs may be. Experts tell SurvivorNet that every woman with ovarian cancer should get a genetic test to determine if they have a mutation called BRCA, because the mutation enables PARP inhibitors to function much more powerfully. Importantly, there is increasing data that even women without BRCA mutations can still derive some benefit from these drugs.

Read More
PARP inhibitors interrupt the process of single stranded DNA repair, an essential part of cell replication. Defects in DNA repair ultimately cause cell death. PARP inhibitors work best when there is a second error in DNA repair, such as that caused by a mutation in BRCA. BRCA is a critical player in homologous recombination, a highly effective double stranded DNA repair process. BRCA is not the only important part of homologous recombination, other genes are involved. The label homologous recombination deficient (HRD) indicates a tumor which has one of many possible errors in the double stranded DNA repair process of homologous recombination.

Which PARP Inhibitors are Available For Newly-Diagnosed Epithelial ovarian cancer?

  1. The PARP inhibitor Zejula (niraparib) has been approved by the FDA for all women with newly-diagnosed ovarian cancer regardless of whether the tumor is HRD or whether the patient has the BRCA gene. The drug is used after successful treatment with a platinum-based chemotherapy, the mainstay chemotherapy for ovarian cancer.
  2. Due to limited benefit in progression free survival seen in the absence of HRD, gynecologic oncologists differ on whether PARP inhibitors should be universally recommended in the "upfront maintenance setting." Each patient should be made aware of risks and benefits to PARP inhibitor maintenance and decide with their oncologist what is the best treatment plan for them.
  3. The PARP inhibitor Lynparza (olaparib) is approved for women newly diagnosed with ovarian cancer and with a germline or somatic mutation in BRCA1/2.
  4. Lynparza is also approved in combination with Avastin (bevacizumab) for women with HRD.  Avastin is a blood vessel growth inhibitor, which works by starving the tumor of vital nutrients needed to grow.
Using PARPs To Treat Recurrence

Unfortunately, too often, ovarian cancer comes back.

For women with ovarian cancer who have had a recurrence and responded to platinum-based chemotherapy, Lynparza, Zejula and another PARP inhibitor called Rubraca (rucaparib) are FDA approved for use as a maintenance therapy, regardless of whether a woman has a BRCA mutation or HRD.

For some women who have had prior chemotherapy treatments, Rubraca, Zejula or Lynparza may also be options. These uses are based on factors such as number of prior therapies and BRCA mutation or HRD.

The Future of PARP Inhibitor Treatment

PARP inhibitor combinations also must be further studied to figure out how to expand the usage and efficacy.

Then there's the matter of possible resistance to the PARP inhibitors. Sometimes patients will become resistant to PARP inhibitors. Researchers are trying to understand how best to use other agents and methods to neutralize the potential for resistances. Fortunately, there are a lot of labs working on the answer to that question now, in addition to conducting further clinical trials.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Ursula Matulonis is the Chief of the Division of Gynecologic Oncology at Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute. Read More

PARP Inhibitors For Maintenance

PARP inhibitors are an important therapy that traditionally were used after a recurrence of ovarian cancer. Now however, they are also being used for maintenance therapy after initial treatment.

NOW
PLAYING
PARP Inhibitors: Leading Experts Say The Fatigue You Get From Therapy is Often Worth The Benefit
NOW
PLAYING
Evaluating Bevacizumab and PARP Inhibitors as Important Treatment Options
NOW
PLAYING
PARP Inhibitors -- Advancing Ovarian Cancer Treatment
NOW
PLAYING
Differences Between Types of PARP Inhibitors
NOW
PLAYING
Olaparib for Prevention of Ovarian Cancer Recurrence
NOW
PLAYING
Should PARP Inhibitors be Given to All Patients?

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... ovarian cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

Continue The Journey

Explore: Recurrence

Related Articles

Sylvester Stallone’s Movie Nemesis ‘Ivan Drago’ Actor Dolph Lundgren, 67, Defies The Odd & Is ‘Finally Cancer Free’ After Undergoing Treatment To Removed His ‘Last Tumor’

Overview

Why Some Gliomas Return After Surgery or Radiation Therapy

The World Lost ‘That’s Amore’ Legendary Singer Dean Martin To Lung Cancer At Age 78; Learn About The Huge Incredible Progress In Treatment

Overview

New FDA Approval: Vyloy (Zolbetuximab) — A Promising Option for Advanced Gastric Cancer

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider